10 research outputs found

    Effect of Inhaled Xenon on Cardiac Function in Comatose Survivors of Out-of-Hospital Cardiac Arrest—A Substudy of the Xenon in Combination With Hypothermia After Cardiac Arrest Trial

    Get PDF
    OBJECTIVES: This explorative substudy aimed at determining the effect ofinhaled xenon on left ventricular function by echocardiography in comatose survivorsof out-of-hospital cardiac arrest.DESIGN: A randomized two-group single-blinded phase 2 clinical drug trial.SETTING: A multipurpose ICU in two university hospitals.PATIENTS: Of the 110 randomized comatose survivors after out-of-hospital cardiacarrest with a shockable rhythm in the xenon in combination with hypothermiaafter cardiac arrest trial, 38 patients (24–76 yr old) with complete echocardiographywere included in this study.INTERVENTIONS: Patients were randomized to receive either inhaled xenoncombined with hypothermia (33 C) for 24 hours or hypothermia treatment alone.Echocardiography was performed at hospital admission and 24 4 hours afterhypothermia.MEASUREMENTS AND MAIN RESULTS: Left ventricular ejection fraction,myocardial longitudinal systolic strain, and diastolic function were analyzedblinded to treatment. There were 17 xenon and 21 control patients in whom echocardiographywas completed. Clinical characteristics did not differ significantlybetween the groups. At admission, ejection fraction was similar in xenon and controlpatients (39% 10% vs 38% 11%; p = 0.711) but higher in xenon thancontrol patients after hypothermia (50% 10% vs 42% 10%; p = 0.014).Global longitudinal systolic strain was similar in xenon and control patients atadmission (–9.0% 3.8% vs –8.1% 3.6%; p = 0.555) but better in xenonthan control patients after hypothermia (–14.4.0% 4.0% vs –10.5% 4.0%;p = 0.006). In patients with coronary artery disease, longitudinal strain improved inthe nonischemic myocardial segments in xenon patients. There were no changesin diastolic function between the groups.</p

    Inhaled Xenon Attenuates Myocardial Damage in Comatose Survivors of Out-of-Hospital Cardiac Arrest The Xe-Hypotheca Trial

    Get PDF
    Marjaana Tiainen on Xe-HYPOTHECA Study Grp -työryhmän jäsen.BACKGROUND The authors previously reported that inhaled xenon combined with hypothermia attenuates brain white matter injury in comatose survivors of out-of-hospital cardiac arrest (OHCA). OBJECTIVES A pre-defined secondary objective was to assess the effect of inhaled xenon on myocardial ischemic damage in the same study population. METHODS A total of 110 comatose patients who had experienced OHCA from a cardiac cause were randomized to receive either inhaled xenon (40% end-tidal concentration) combined with hypothermia (33 degrees C) for 24 h (n = 55; xenon group) or hypothermia treatment alone (n = 55; control group). Troponin-T levels were measured at hospital admission, and at 24 h, 48 h, and 72 h post-cardiac arrest. All available cases were analyzed for troponin-T release. RESULTS Troponin-T measurements were available from 54 xenon patients and 54 control patients. The baseline characteristics did not differ significantly between the groups. After adjustments for age, sex, study site, primary coronary percutaneous intervention (PCI), and norepinephrine dose, the mean +/- SD post-arrival incremental change of the ln-transformed troponin-T at 72 h was 0.79 +/- 1.54 in the xenon group and 1.56 +/- 1.38 in the control group (adjusted mean difference -0.66; 95% confidence interval: -1.16 to -0.16; p = 0.01). The effect of xenon on the change in the troponin-T values did not differ in patients with or without PCI or in those with a diagnosis of ST-segment elevation myocardial infarction (group by PCI or ST-segment elevation myocardial infarction interaction effect; p = 0.86 and p = 0.71, respectively). CONCLUSIONS Among comatose survivors of OHCA, in comparison with hypothermia alone, inhaled xenon combined with hypothermia suggested a less severe myocardial injury as demonstrated by the significantly reduced release of troponin-T. (C) 2017 by the American College of Cardiology Foundation.Peer reviewe
    corecore